Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?
Daniel Martin SimadibrataElvira LesmanaYeong Yeh LeePublished in: Expert opinion on investigational drugs (2024)
PCAB has gained interest in recent years, with pharmacokinetics and pharmacodynamics properties surpassing PPI. Although recent data on PCABs, which comprised mainly of Vonoprazan, have shown promising results, more randomized controlled trials for other PCAB drugs are needed to elucidate and confirm the superiority of this drug class to PPI, the current first-line treatment of EE.